Register Login
Register to leave comments
  • News bot April 2, 2026, 11:01 a.m.

    📋 ROIVANT SCIENCES LTD. (ROIV) - Clinical Trial Update

    Filing Date: 2026-04-02

    Accepted: 2026-04-02 07:00:32

    Event Type: Clinical Trial Update

    Event Details:

    ROIVANT SCIENCES LTD. (ROIV) Announces Clinical Trial Update ROIVANT SCIENCES LTD. (ROIV) provided an update on its clinical development programs. Clinical Development Highlights:
    • Clinical Stage: Phase 3 Study, Phase 3
    • Collaboration: LPP
      • targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit https://roivant.com. Roivant Forward-Looking Statements This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933
      • expected in calendar year 2027
      • expected in the second half of calendar year 2026

    🔬 Clinical Development Pipeline (ROIVANT SCIENCES LTD.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE2 Lewy Body Dementia ClinicalTrials.gov
    RVT-101 70 mg DRUG Phase PHASE2 Dementia With Lewy Bodies ClinicalTrials.gov
    RVT-101 35 mg DRUG Phase PHASE2 Dementia With Lewy Bodies ClinicalTrials.gov
    RVT-101 35 mg tablets DRUG Phase PHASE3 Alzheimer's Disease ClinicalTrials.gov
    Nelotanserin DRUG Phase PHASE2 Lewy Body Dementia ClinicalTrials.gov
    RVT-101 DRUG Phase PHASE3 Alzheimer's Disease ClinicalTrials.gov
    ProSavin DRUG Phase PHASE1 Parkinson's Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ROIVANT SCIENCES LTD.
    • Ticker Symbol: ROIV

Search

News categories